Skip to Main Content

Someone needs to tell Michel Vounatsos that he suffers from a terrible case of tin ear syndrome.

At a time when many Americans are increasingly angry over the cost of medicines, the Biogen chief executive last June slapped a $56,000 price tag on its newly approved Alzheimer’s treatment.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Create a display name to comment

This name will appear with your comment